Popular Trials
Polyphenol
Grape Seed Extract for Prostate Cancer
Recruiting1 award
Aurora, Colorado
This trial involves patients taking a grape seed extract supplement to help manage their prostate health. The supplement is believed to protect cells and reduce inflammation. Patients' PSA levels will be monitored to assess the effectiveness of the treatment.
Popular Filters
Trials for Adenocarcinoma Patients
Behavioural Intervention
Home-Based Exercise for Prostate Cancer
Recruiting1 award3 criteria
Charlottesville, Virginia
This trial involves two different exercise programs that can be done at home: one using a stationary exercise bike (Arm A) and the other involving walking (Arm B). The study will include 24 patients
Hormone Therapy
DFMO + Testosterone + Enzalutamide for Prostate Cancer
Recruiting1 awardPhase 2
Baltimore, Maryland
This trial involves treating patients with advanced prostate cancer that hasn't responded to other treatments. The treatment plan includes taking DFMO, followed by a combination of DFMO and testosterone, and then switching to another medication. These drugs work together to stop cancer cells from growing by blocking important processes they need to survive.
Alkylating agents
Carboplatin vs Olaparib for Prostate Cancer
Recruiting1 awardPhase 2
West Los Angeles, California
This trial is comparing the efficacy of two treatments for patients with metastatic castrate resistant prostate cancer who have tumors containing BRCA1, BRCA2 or PALB2 inactivating DNA mutations.
Trials for Prostate Carcinoma Patients
Behavioural Intervention
Home-Based Exercise for Prostate Cancer
Recruiting1 award3 criteria
Charlottesville, Virginia
This trial involves two different exercise programs that can be done at home: one using a stationary exercise bike (Arm A) and the other involving walking (Arm B). The study will include 24 patients
Hormone Therapy
DFMO + Testosterone + Enzalutamide for Prostate Cancer
Recruiting1 awardPhase 2
Baltimore, Maryland
This trial involves treating patients with advanced prostate cancer that hasn't responded to other treatments. The treatment plan includes taking DFMO, followed by a combination of DFMO and testosterone, and then switching to another medication. These drugs work together to stop cancer cells from growing by blocking important processes they need to survive.
Alkylating agents
Carboplatin vs Olaparib for Prostate Cancer
Recruiting1 awardPhase 2
West Los Angeles, California
This trial is comparing the efficacy of two treatments for patients with metastatic castrate resistant prostate cancer who have tumors containing BRCA1, BRCA2 or PALB2 inactivating DNA mutations.
Trials for Metastatic Patients
Behavioural Intervention
Home-Based Exercise for Prostate Cancer
Recruiting1 award3 criteria
Charlottesville, Virginia
This trial involves two different exercise programs that can be done at home: one using a stationary exercise bike (Arm A) and the other involving walking (Arm B). The study will include 24 patients
Hormone Therapy
DFMO + Testosterone + Enzalutamide for Prostate Cancer
Recruiting1 awardPhase 2
Baltimore, Maryland
This trial involves treating patients with advanced prostate cancer that hasn't responded to other treatments. The treatment plan includes taking DFMO, followed by a combination of DFMO and testosterone, and then switching to another medication. These drugs work together to stop cancer cells from growing by blocking important processes they need to survive.
Alkylating agents
Carboplatin vs Olaparib for Prostate Cancer
Recruiting1 awardPhase 2
West Los Angeles, California
This trial is comparing the efficacy of two treatments for patients with metastatic castrate resistant prostate cancer who have tumors containing BRCA1, BRCA2 or PALB2 inactivating DNA mutations.
Antiandrogen
Enzalutamide + ADT for Metastatic Prostate Cancer
Recruiting3 awardsPhase 3
Boston, Massachusetts
This trial is testing whether a new drug, enzalutamide, is more effective than a conventional non-steroidal anti androgen (NSAA), when combined with a luteinizing hormone releasing hormone analog (LHRHA) or surgical castration, as first line androgen deprivation therapy (ADT) for newly diagnosed metastatic prostate cancer.
Phase 3 Trials
Antiandrogen
Enzalutamide + ADT for Metastatic Prostate Cancer
Recruiting3 awardsPhase 3
Boston, Massachusetts
This trial is testing whether a new drug, enzalutamide, is more effective than a conventional non-steroidal anti androgen (NSAA), when combined with a luteinizing hormone releasing hormone analog (LHRHA) or surgical castration, as first line androgen deprivation therapy (ADT) for newly diagnosed metastatic prostate cancer.
Hormone Therapy
Androgen Ablation Therapy + Chemotherapy for Prostate Cancer
Recruiting2 awardsPhase 3
Anchorage, Alaska
This trial is studying androgen-ablation therapy and docetaxel to see how well they work compared to androgen-ablation therapy alone in treating patients with metastatic prostate cancer.
Trials With No Placebo
Behavioural Intervention
Home-Based Exercise for Prostate Cancer
Recruiting1 award3 criteria
Charlottesville, Virginia
This trial involves two different exercise programs that can be done at home: one using a stationary exercise bike (Arm A) and the other involving walking (Arm B). The study will include 24 patients
Hormone Therapy
DFMO + Testosterone + Enzalutamide for Prostate Cancer
Recruiting1 awardPhase 2
Baltimore, Maryland
This trial involves treating patients with advanced prostate cancer that hasn't responded to other treatments. The treatment plan includes taking DFMO, followed by a combination of DFMO and testosterone, and then switching to another medication. These drugs work together to stop cancer cells from growing by blocking important processes they need to survive.
Alkylating agents
Carboplatin vs Olaparib for Prostate Cancer
Recruiting1 awardPhase 2
West Los Angeles, California
This trial is comparing the efficacy of two treatments for patients with metastatic castrate resistant prostate cancer who have tumors containing BRCA1, BRCA2 or PALB2 inactivating DNA mutations.
Antiandrogen
Enzalutamide + ADT for Metastatic Prostate Cancer
Recruiting3 awardsPhase 3
Boston, Massachusetts
This trial is testing whether a new drug, enzalutamide, is more effective than a conventional non-steroidal anti androgen (NSAA), when combined with a luteinizing hormone releasing hormone analog (LHRHA) or surgical castration, as first line androgen deprivation therapy (ADT) for newly diagnosed metastatic prostate cancer.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.